Glyconia

Company Overview

Snapshot

Founded in June 2022 by Vered Padler-Karavani, Glyconia operates with 1–10 employees. The company is in the Pre-Funding stage and ceased operations in January 2024.

Business overview

Glyconia is a Health Tech & Life Sciences company focused on developing immunotherapy solutions for cancer. The company's core technology involves a proprietary platform that identifies and targets cancer cells based on their unique sugar-coating, which differs from healthy cells. Glyconia is developing breakthrough CAR-T immunotherapy to specifically target cancer cell-surface glycosylation with high efficiency and potency, operating within the pharmaceuticals, cancer therapy, and biotechnology sectors.

Company Intelligence Q&A

What is Glyconia's primary focus?

Glyconia focuses on developing immunotherapy solutions for cancer by targeting the unique sugar-coating on cancer cells, aiming to differentiate them from healthy cells.

Who founded Glyconia?

Glyconia was founded by Vered Padler-Karavani, who also serves as the company's President and CTO.

When was Glyconia founded?

Glyconia was founded in June 2022.

What is Glyconia's current operational status?

Glyconia is currently non-active and ceased operations in January 2024.

What technology does Glyconia utilize?

Glyconia utilizes a proprietary technology platform to develop CAR-T immunotherapy that specifically targets cancer cell-surface glycosylation, based on the unique sugar-coating of cancer cells.